Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Pipeline Monitor
Thyroid cancer blockbuster nears EU market
Sanofi scores a vaccine approval while BI/Lilly and Novo Nordisk advance new diabetes drugs and Eisai closes on market permission for a potential blockbuster in thyroid cancer.
Working Life
Giving evidence in court: just part of the job?
The evidence of company staff played a key role in the recent ACCC v Pfizer and Novartis v Bayer cases. Any employee could be called to the stand, lawyers say, so what could you expect?
Approvals Action
Generics dominate the week
Additions to the ranks of PBS listed generics constituted the main action on the drugs register during the week.
Special Report
Generics and originators face off in biosim battle
Who will dominate the biosim market? Established generics makers and originators with biosimilars in the pipeline are set to battle for Australia's developing market.
Open Forum
Funding new gen cancer drugs demands co-operation
Professor John Zalcberg says industry, government, clinicians and consumers must co-operate to ensure access to new generation of cancer medications.